A Phase 2 interventional study of Humalog and Humulin-R in Type 1 Diabetes Mellitus, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by Halozyme Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 51st largest by enrollment, is one of 3 that started in 2008, is one of 7 in phase 2, and was the 10th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–99
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 18+
By country, each count listing its studies:
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2002; this study’s year is marked. 3 started in 2008.
This study's enrollment of 22 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 69 interventional studies. Of the 60 that completed or were terminated, 33 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 69 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 7 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
1 of the studies testing Insulin Lispro in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA) approved medications for the treatment of diabetes mellitus. Recombinant human hyaluronidase PH20 (rHuPH20) is approved by the FDA for use as an aid in the absorption and dispersion of other injectable drugs. In this study, rHuPH20 will be co-administered with both Humalog and Humulin-R in order to determine if it improves the absorption of these insulins to more closely mimic the body's natural increase in insulin in response to a meal.
Participants received all 4 interventions in the same order.
Dose-finding visits were conducted to identify the appropriate dose of Humalog and Humulin-R. For each Humalog dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humalog, corresponding to a mass concentration of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). For each Humulin-R dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humulin-R, corresponding to a mass concentration of 20.0 μg/mL rHuPH20 (at final concentration of 100 U/mL of Humulin-R).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified. Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal. Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified. Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal. Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was \<160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL. All dose finding visits and interventions were separated by 3-10 days.
Drug: Humalog · Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20) · Other: Liquid meal
Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60)
AUC was derived as the area under the serum insulin concentration profile from 0 to time "t." Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; and at 20, 30, 45, and 60 mins postdose.
Time frame: Predose up to 60 minutes postdose
Maximum Serum Insulin Concentration (Cmax)
Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.
Time frame: Predose up to 480 minutes postdose
Time to Maximum Serum Insulin Concentration (Tmax)
Tmax was determined as the timepoint where the maximum of all valid concentration measurements for each measurement series was observed. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.
Time frame: Predose up to 480 minutes postdose
Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG])
AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 140 milligrams per deciliter (mg/dL) within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before; at 3, 6, 9, 12, 15, 20, 25 minutes; and every 10 minutes from minute 30 to 240 postdose.
Time frame: Predose up to 4 hours after injection of study drug
| Milestone | First Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R |
|---|---|
| Started | 22 |
| Received at least one dose of study drug | 22 |
| Completed | 22 |
| Not completed | 0 |
| Milestone | First Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R |
|---|---|
| Started | 22 |
| Completed | 22 |
| Not completed | 0 |
| Milestone | First Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R |
|---|---|
| Started | 22 |
| Received at least one dose of study drug | 22 |
| Completed | 22 |
| Not completed | 0 |
| Milestone | First Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R |
|---|---|
| Started | 22 |
| Completed | 22 |
| Not completed | 0 |
| Milestone | First Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R |
|---|---|
| Started | 22 |
| Received at least one dose of study drug | 22 |
| Completed | 22 |
| Not completed | 0 |
| Milestone | First Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R |
|---|---|
| Started | 22 |
| Completed | 22 |
| Not completed | 0 |
| Milestone | First Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R |
|---|---|
| Started | 22 |
| Received at least one dose of study drug | 21 |
| Completed | 21 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
AUC was derived as the area under the serum insulin concentration profile from 0 to time "t." Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; and at 20, 30, 45, and 60 mins postdose.
| nanomole*minute per liter (nmol*min/L) | Humalog + rHuPH20 | Humalog Alone | Humulin-R + rHuPH20 | Humulin-R Alone |
|---|---|---|---|---|
| Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60) | 12346.67 ± 4996.79 | 8297.62 ± 3670.03 | 11607.65 ± 6770.61 | 4331.76 ± 3068.10 |
Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.
| Picomoles per liter (pmol/L) | Humalog + rHuPH20 | Humalog Alone | Humulin-R + rHuPH20 | Humulin-R Alone |
|---|---|---|---|---|
| Maximum Serum Insulin Concentration (Cmax) | 307.67 ± 125.73 | 226.38 ± 85.51 | 285.88 ± 139.54 | 165.05 ± 68.98 |
Tmax was determined as the timepoint where the maximum of all valid concentration measurements for each measurement series was observed. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.
| minutes | Humalog + rHuPH20 | Humalog Alone | Humulin-R + rHuPH20 | Humulin-R Alone |
|---|---|---|---|---|
| Time to Maximum Serum Insulin Concentration (Tmax) | 30.24 ± 8.73 | 48.57 ± 13.34 | 57.06 ± 30.83 | 116.76 ± 65.02 |
AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 140 milligrams per deciliter (mg/dL) within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before; at 3, 6, 9, 12, 15, 20, 25 minutes; and every 10 minutes from minute 30 to 240 postdose.
| minutes*milligrams per deciliter | Humalog + rHuPH20 | Humalog Alone | Humulin-R + rHuPH20 | Humulin-R Alone |
|---|---|---|---|---|
| Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG]) | 111 (35 to 357) | 526 (164 to 1685) | 181 (57 to 581) | 1,238 (343 to 4466) |
Collected over Adverse event data collected from Day 1 through to the end of the study, for up to 80 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Humalog + rHuPH20 | — | 0/22 (0%) | 14/22 (63.6%) |
| Humalog Alone | — | 0/22 (0%) | 15/22 (68.2%) |
| Humulin-R + rHuPH20 | — | 0/22 (0%) | 18/22 (81.8%) |
| Humulin-R Alone | — | 0/21 (0%) | 18/21 (85.7%) |
| Event | Humalog + rHuPH20 | Humalog Alone | Humulin-R + rHuPH20 | Humulin-R Alone |
|---|---|---|---|---|
| Blood glucose decreasedInvestigations | 13/22 | 11/22 | 14/22 | 14/21 |
| HypoglycaemiaMetabolism and nutrition disorders | 5/22 | 4/22 | 9/22 | 7/21 |
| HeadacheNervous system disorders | 1/22 | 3/22 | 3/22 | 1/21 |
| Injection site erythemaGeneral disorders | 0/22 | 0/22 | 2/22 | 0/21 |
| Viral infectionInfections and infestations | 0/22 | 0/22 | 0/22 | 1/21 |
| Joint sprainInjury, poisoning and procedural complications | 0/22 | 0/22 | 0/22 | 1/21 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/22 | 0/22 | 1/22 | 1/21 |
| NauseaGastrointestinal disorders | 0/22 | 1/22 | 0/22 | 0/21 |
| VomitingGastrointestinal disorders | 0/22 | 1/22 | 1/22 | 0/21 |
| Upper respiratory tract infectionInfections and infestations | 0/22 | 1/22 | 0/22 | 0/21 |
All participants who received at least 1 dose of Humalog, Humulin-R, or recombinant human hyaluronidase PH20 (rHuPH20).
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 40.7 ± 10.73 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 7 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 18 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 19 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Overall Study |
|---|---|
| United States | 22 |
The record gives a start of Oct 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Lispro · Insulin, Regular, Human · Hyaluronidase (human recombinant)